DB:6MX

Stock Analysis Report

Executive Summary

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR).


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Eidos Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6MX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.9%

6MX

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

226.3%

6MX

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 6MX exceeded the German Biotechs industry which returned 10% over the past year.

Return vs Market: 6MX exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

6MXIndustryMarket
7 Day2.9%0.4%-0.9%
30 Day-1.2%-3.2%-0.4%
90 Day-4.5%4.6%2.3%
1 Year226.3%226.3%10.3%10.0%16.3%12.8%
3 Yearn/a49.4%47.8%15.8%5.7%
5 Yearn/a13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Eidos Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Eidos Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6MX (€49.4) is trading below our estimate of fair value (€196.53)

Significantly Below Fair Value: 6MX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6MX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6MX is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6MX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6MX is overvalued based on its PB Ratio (12.2x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Eidos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-17.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6MX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6MX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6MX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6MX's revenue (63.3% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: 6MX's revenue (63.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6MX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Eidos Therapeutics performed over the past 5 years?

18.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 6MX is currently unprofitable.

Growing Profit Margin: 6MX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6MX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 6MX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6MX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6MX has a negative Return on Equity (-17.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Eidos Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 6MX's short term assets ($171.3M) exceed its short term liabilities ($10.1M).

Long Term Liabilities: 6MX's short term assets ($171.3M) exceed its long term liabilities ($4.9M).


Debt to Equity History and Analysis

Debt Level: 6MX is debt free.

Reducing Debt: 6MX had no debt 5 years ago.


Balance Sheet

Inventory Level: 6MX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 6MX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6MX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6MX has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -58.3% each year.


Next Steps

Dividend

What is Eidos Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 6MX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6MX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6MX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6MX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6MX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Neil Kumar (40yo)

3.9yrs

Tenure

US$823,148

Compensation

Dr. Neil Kumar, Ph.D., is a co-founder and has served as BridgeBio Pharma, Inc.'s Chief Executive Officer and a member of board of directors since April 2015. He serves as the Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD823.15K) is below average for companies of similar size in the German market ($USD1.52M).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Neil Kumar
CEO & Director3.9yrsUS$823.15kno data
Isabella Graef
Founder & Board Advisor0yrsUS$150.00kno data
Uma Sinha
Chief Scientific Officer & Director0.2yrsUS$5.48m0.88% $16.3m
Cameron Turtle
Chief Business Officer1.3yrsUS$3.41m0.21% $4.0m
Hoyoung Huh
Consultant1.2yrsUS$724.60kno data
Jonathan Fox
President & Chief Medical Officer3.3yrsUS$1.71m1.12% $20.8m
Franco Valle
Senior VP of Finance & Principal Accounting Officer0.08yrsno datano data
Matt Outen
Acting Chief Commercial Officer0yrsno datano data

2.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 6MX's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Neil Kumar
CEO & Director3.9yrsUS$823.15kno data
Isabella Graef
Founder & Board Advisor0yrsUS$150.00kno data
Uma Sinha
Chief Scientific Officer & Director0.2yrsUS$5.48m0.88% $16.3m
Eric Aguiar
Independent Director1.9yrsUS$626.28kno data
Ali Satvat
Independent Director1.7yrsUS$610.45kno data
Rajeev Shah
Independent Director1.9yrsUS$622.32kno data
William Lis
Independent Director1.2yrsUS$400.40kno data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Board: 6MX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 6MX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 174.7%.


Top Shareholders

Company Information

Eidos Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eidos Therapeutics, Inc.
  • Ticker: 6MX
  • Exchange: DB
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.008b
  • Listing Market Cap: US$1.849b
  • Shares outstanding: 37.50m
  • Website: https://www.eidostx.com

Number of Employees


Location

  • Eidos Therapeutics, Inc.
  • 101 Montgomery Street
  • Suite 2550
  • San Francisco
  • California
  • 94101
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EIDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
6MXDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. operates as a subsidiary of BridgeBio Pharma LLC. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:39
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.